Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 506260 | NSE: ANUHPHR

Anuh Pharma Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 12, 2025, 9:31 am

Market Cap 793 Cr.
Current Price 158
High / Low 265/150
Stock P/E15.8
Book Value 60.5
Dividend Yield1.57 %
ROCE25.6 %
ROE19.5 %
Face Value 5.00
PEG Ratio1.31

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Anuh Pharma Ltd

Competitors of Anuh Pharma Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of Anuh Pharma Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 132129116115139157161150172164138166160
Expenses 120115105102126143148132148145127149145
Operating Profit 12141113121414182419111715
OPM % 9%11%10%12%9%9%9%12%14%12%8%10%9%
Other Income 0112213243431
Interest 1-000000000000
Depreciation 3322222222222
Profit before tax 9121013121315182520121813
Tax % 16%26%24%23%23%25%24%23%24%22%22%17%22%
Net Profit 7971091012141915101510
EPS in Rs 1.491.781.461.981.861.922.342.763.813.071.903.002.06

Last Updated: February 28, 2025, 3:32 pm

Below is a detailed analysis of the quarterly data for Anuh Pharma Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹160.00 Cr.. The value appears to be declining and may need further review. It has decreased from 166.00 Cr. (Sep 2024) to ₹160.00 Cr., marking a decrease of 6.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹145.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 149.00 Cr. (Sep 2024) to ₹145.00 Cr., marking a decrease of 4.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Sep 2024) to ₹15.00 Cr., marking a decrease of 2.00 Cr..
  • For OPM %, as of Dec 2024, the value is 9.00%. The value appears to be declining and may need further review. It has decreased from 10.00% (Sep 2024) to 9.00%, marking a decrease of 1.00%.
  • For Other Income, as of Dec 2024, the value is ₹1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Sep 2024) to ₹1.00 Cr., marking a decrease of 2.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 2.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Sep 2024) to ₹13.00 Cr., marking a decrease of 5.00 Cr..
  • For Tax %, as of Dec 2024, the value is 22.00%. The value appears to be increasing, which may not be favorable. It has increased from 17.00% (Sep 2024) to 22.00%, marking an increase of 5.00%.
  • For Net Profit, as of Dec 2024, the value is ₹10.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Sep 2024) to ₹10.00 Cr., marking a decrease of 5.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 2.06. The value appears to be declining and may need further review. It has decreased from ₹3.00 (Sep 2024) to 2.06, marking a decrease of ₹0.94.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 2:04 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 243266284326206238321307432487527647627
Expenses 225242253289183220291284387439476571566
Operating Profit 18243138231830234547527661
OPM % 7%9%11%12%11%8%9%8%10%10%10%12%10%
Other Income 2454875411561211
Interest 1111101122111
Depreciation 2232222715121098
Profit before tax 18253238282332193939477863
Tax % 29%31%31%32%27%29%28%25%26%22%24%23%
Net Profit 13182226201723142831366050
EPS in Rs 2.503.514.395.154.003.304.662.865.686.107.2211.9910.03
Dividend Payout % 40%37%27%24%31%42%29%48%26%29%28%21%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)38.46%22.22%18.18%-23.08%-15.00%35.29%-39.13%100.00%10.71%16.13%66.67%
Change in YoY Net Profit Growth (%)0.00%-16.24%-4.04%-41.26%8.08%50.29%-74.42%139.13%-89.29%5.41%50.54%

Anuh Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: November 14, 2024, 5:52 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 44413131313132525252525
Reserves 718297107128137152150166189216266278
Borrowings 1002024451441314
Other Liabilities 60776771485771119128129163152117
Total Liabilities 136163168193189209240326333347405446434
Fixed Assets 1012918171721847161534946
CWIP 30000634000002
Investments 19274343706639803143919798
Other Assets 104124116131101120147163230243261300288
Total Assets 136163168193189209240326333347405446434

Below is a detailed analysis of the balance sheet data for Anuh Pharma Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹25.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹278.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹266.00 Cr. (Mar 2024) to ₹278.00 Cr., marking an increase of 12.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from ₹3.00 Cr. (Mar 2024) to ₹14.00 Cr., marking an increase of 11.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹117.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹152.00 Cr. (Mar 2024) to ₹117.00 Cr., marking a decrease of 35.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹434.00 Cr.. The value appears to be improving (decreasing). It has decreased from ₹446.00 Cr. (Mar 2024) to ₹434.00 Cr., marking a decrease of 12.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹46.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹49.00 Cr. (Mar 2024) to ₹46.00 Cr., marking a decrease of 3.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹2.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹0.00 Cr. (Mar 2024) to ₹2.00 Cr., marking an increase of 2.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹98.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹97.00 Cr. (Mar 2024) to ₹98.00 Cr., marking an increase of 1.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹288.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹300.00 Cr. (Mar 2024) to ₹288.00 Cr., marking a decrease of 12.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹434.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹446.00 Cr. (Mar 2024) to ₹434.00 Cr., marking a decrease of 12.00 Cr..

Notably, the Reserves (₹278.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

No data available for this post.

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow17.0024.0031.0036.0023.0016.0026.00-22.0031.0043.0051.0073.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days821028884100109859690102118107
Inventory Days433327357264649890776657
Days Payable86102797710210589166133117139105
Cash Conversion Cycle393336427068612848624658
Working Capital Days454243517983704468706168
ROCE %26%31%33%35%19%14%19%10%16%18%19%26%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters70.43%70.59%70.59%70.59%70.59%70.59%70.59%69.94%69.91%69.91%69.91%69.91%
FIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.03%0.03%0.02%0.02%
DIIs0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.10%0.00%0.00%0.00%
Public29.56%29.42%29.41%29.40%29.40%29.39%29.40%30.05%29.96%30.05%30.06%30.06%
No. of Shareholders21,12320,74020,45220,47019,96919,42319,06620,51922,23723,49423,91024,048

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 5.005.005.005.005.00
Basic EPS (Rs.) 11.987.226.105.675.71
Diluted EPS (Rs.) 11.987.226.105.675.71
Cash EPS (Rs.) 13.709.158.488.688.52
Book Value[Excl.RevalReserv]/Share (Rs.) 58.1148.1442.6638.0464.74
Book Value[Incl.RevalReserv]/Share (Rs.) 58.1148.1442.6638.0464.74
Dividend / Share (Rs.) 2.502.001.751.502.75
Revenue From Operations / Share (Rs.) 129.11105.2697.1186.20122.51
PBDIT / Share (Rs.) 17.4111.4510.3911.0010.77
PBIT / Share (Rs.) 15.709.528.007.997.96
PBT / Share (Rs.) 15.639.477.817.697.64
Net Profit / Share (Rs.) 11.987.226.105.675.71
PBDIT Margin (%) 13.4810.8710.6912.768.78
PBIT Margin (%) 12.159.048.239.276.49
PBT Margin (%) 12.108.998.038.926.24
Net Profit Margin (%) 9.286.856.276.584.66
Return on Networth / Equity (%) 20.6214.9914.2914.918.81
Return on Capital Employeed (%) 26.8419.5718.5320.7312.18
Return On Assets (%) 13.478.938.808.544.38
Total Debt / Equity (X) 0.010.000.010.070.27
Asset Turnover Ratio (%) 1.521.401.431.311.08
Current Ratio (X) 2.201.911.981.701.37
Quick Ratio (X) 1.711.461.371.120.99
Inventory Turnover Ratio (X) 6.624.944.364.534.59
Dividend Payout Ratio (NP) (%) 16.6824.2324.590.0096.33
Dividend Payout Ratio (CP) (%) 14.6019.1117.670.0064.58
Earning Retention Ratio (%) 83.3275.7775.410.003.67
Cash Earning Retention Ratio (%) 85.4080.8982.330.0035.42
Interest Coverage Ratio (X) 246.74262.7754.1636.8834.06
Interest Coverage Ratio (Post Tax) (X) 170.85166.6632.8020.0319.06
Enterprise Value (Cr.) 1223.09392.34417.88446.02334.07
EV / Net Operating Revenue (X) 1.890.740.851.031.09
EV / EBITDA (X) 14.026.848.038.0912.38
MarketCap / Net Operating Revenue (X) 1.900.750.881.050.95
Retention Ratios (%) 83.3175.7675.400.003.66
Price / BV (X) 4.231.652.012.371.80
Price / Net Operating Revenue (X) 1.900.750.881.050.95
EarningsYield 0.040.090.070.060.04

After reviewing the key financial ratios for Anuh Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 7.22 (Mar 23) to 11.98, marking an increase of 4.76.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 7.22 (Mar 23) to 11.98, marking an increase of 4.76.
  • For Cash EPS (Rs.), as of Mar 24, the value is 13.70. This value is within the healthy range. It has increased from 9.15 (Mar 23) to 13.70, marking an increase of 4.55.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 58.11. It has increased from 48.14 (Mar 23) to 58.11, marking an increase of 9.97.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 58.11. It has increased from 48.14 (Mar 23) to 58.11, marking an increase of 9.97.
  • For Dividend / Share (Rs.), as of Mar 24, the value is 2.50. This value is within the healthy range. It has increased from 2.00 (Mar 23) to 2.50, marking an increase of 0.50.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 129.11. It has increased from 105.26 (Mar 23) to 129.11, marking an increase of 23.85.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 17.41. This value is within the healthy range. It has increased from 11.45 (Mar 23) to 17.41, marking an increase of 5.96.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 15.70. This value is within the healthy range. It has increased from 9.52 (Mar 23) to 15.70, marking an increase of 6.18.
  • For PBT / Share (Rs.), as of Mar 24, the value is 15.63. This value is within the healthy range. It has increased from 9.47 (Mar 23) to 15.63, marking an increase of 6.16.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 11.98. This value is within the healthy range. It has increased from 7.22 (Mar 23) to 11.98, marking an increase of 4.76.
  • For PBDIT Margin (%), as of Mar 24, the value is 13.48. This value is within the healthy range. It has increased from 10.87 (Mar 23) to 13.48, marking an increase of 2.61.
  • For PBIT Margin (%), as of Mar 24, the value is 12.15. This value is within the healthy range. It has increased from 9.04 (Mar 23) to 12.15, marking an increase of 3.11.
  • For PBT Margin (%), as of Mar 24, the value is 12.10. This value is within the healthy range. It has increased from 8.99 (Mar 23) to 12.10, marking an increase of 3.11.
  • For Net Profit Margin (%), as of Mar 24, the value is 9.28. This value is within the healthy range. It has increased from 6.85 (Mar 23) to 9.28, marking an increase of 2.43.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 20.62. This value is within the healthy range. It has increased from 14.99 (Mar 23) to 20.62, marking an increase of 5.63.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 26.84. This value is within the healthy range. It has increased from 19.57 (Mar 23) to 26.84, marking an increase of 7.27.
  • For Return On Assets (%), as of Mar 24, the value is 13.47. This value is within the healthy range. It has increased from 8.93 (Mar 23) to 13.47, marking an increase of 4.54.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.01. This value is within the healthy range. It has increased from 0.00 (Mar 23) to 0.01, marking an increase of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 1.52. It has increased from 1.40 (Mar 23) to 1.52, marking an increase of 0.12.
  • For Current Ratio (X), as of Mar 24, the value is 2.20. This value is within the healthy range. It has increased from 1.91 (Mar 23) to 2.20, marking an increase of 0.29.
  • For Quick Ratio (X), as of Mar 24, the value is 1.71. This value is within the healthy range. It has increased from 1.46 (Mar 23) to 1.71, marking an increase of 0.25.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 6.62. This value is within the healthy range. It has increased from 4.94 (Mar 23) to 6.62, marking an increase of 1.68.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 16.68. This value is below the healthy minimum of 20. It has decreased from 24.23 (Mar 23) to 16.68, marking a decrease of 7.55.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 14.60. This value is below the healthy minimum of 20. It has decreased from 19.11 (Mar 23) to 14.60, marking a decrease of 4.51.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 83.32. This value exceeds the healthy maximum of 70. It has increased from 75.77 (Mar 23) to 83.32, marking an increase of 7.55.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 85.40. This value exceeds the healthy maximum of 70. It has increased from 80.89 (Mar 23) to 85.40, marking an increase of 4.51.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 246.74. This value is within the healthy range. It has decreased from 262.77 (Mar 23) to 246.74, marking a decrease of 16.03.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 170.85. This value is within the healthy range. It has increased from 166.66 (Mar 23) to 170.85, marking an increase of 4.19.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 1,223.09. It has increased from 392.34 (Mar 23) to 1,223.09, marking an increase of 830.75.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.89. This value is within the healthy range. It has increased from 0.74 (Mar 23) to 1.89, marking an increase of 1.15.
  • For EV / EBITDA (X), as of Mar 24, the value is 14.02. This value is within the healthy range. It has increased from 6.84 (Mar 23) to 14.02, marking an increase of 7.18.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.90. This value is within the healthy range. It has increased from 0.75 (Mar 23) to 1.90, marking an increase of 1.15.
  • For Retention Ratios (%), as of Mar 24, the value is 83.31. This value exceeds the healthy maximum of 70. It has increased from 75.76 (Mar 23) to 83.31, marking an increase of 7.55.
  • For Price / BV (X), as of Mar 24, the value is 4.23. This value exceeds the healthy maximum of 3. It has increased from 1.65 (Mar 23) to 4.23, marking an increase of 2.58.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.90. This value is within the healthy range. It has increased from 0.75 (Mar 23) to 1.90, marking an increase of 1.15.
  • For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.04, marking a decrease of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Anuh Pharma Ltd as of March 12, 2025 is: ₹151.46

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Anuh Pharma Ltd is Overvalued by 4.14% compared to the current share price 158.00

Intrinsic Value of Anuh Pharma Ltd as of March 12, 2025 is: 169.70

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Anuh Pharma Ltd is Undervalued by 7.41% compared to the current share price 158.00

Last 5 Year EPS CAGR: 12.04%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.17%, which is a positive sign.
  2. The company has higher reserves (156.85 cr) compared to borrowings (6.92 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (377.77 cr) and profit (37.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 60.33, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 49.25, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Anuh Pharma Ltd:
    1. Net Profit Margin: 9.28%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 26.84% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 20.62% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 170.85
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.71
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 15.8 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.01
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Anuh Pharma Ltd. is a Public Limited Listed company incorporated on 19/02/1960 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24230MH1960PLC011586 and registration number is 011586. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 647.00 Cr. and Equity Capital is Rs. 25.06 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Pharmaceuticals3-A, Shivsagar Estate, Mumbai Maharashtra 400018anuh@sk1932.com
http://www.anuhpharma.com
Management
NamePosition Held
Mr. Arun TodarwalChairman & Non-Exe.Director
Mr. Bipin N ShahVice Chairman
Mr. Ritesh B ShahJoint Managing Director
Mr. Vivek B ShahJoint Managing Director
Mr. Sandeep JoshiIndependent Director
Mr. Harmanbhai PatelIndependent Director
Dr.(Ms.) Mita DixitIndependent Director
Mr. Siddharth J ShahIndependent Director
Mr. Pradeep H ThakurIndependent Director
Mr. Ketan ShahNon Executive Director
Mr. Bharat ShahNon Executive Director
Mr. Samir ShahNon Executive Director
Mr. Gaurav S ShahNon Executive Director

FAQ

What is the latest intrinsic value of Anuh Pharma Ltd?

The latest intrinsic value of Anuh Pharma Ltd as on 12 March 2025 is ₹151.46, which is 4.14% lower than the current market price of 158.00, indicating the stock is overvalued by 4.14%. The intrinsic value of Anuh Pharma Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹793 Cr. and recorded a high/low of ₹265/150 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹278 Cr and total liabilities of ₹434 Cr.

What is the Market Cap of Anuh Pharma Ltd?

The Market Cap of Anuh Pharma Ltd is 793 Cr..

What is the current Stock Price of Anuh Pharma Ltd as on 12 March 2025?

The current stock price of Anuh Pharma Ltd as on 12 March 2025 is ₹158.

What is the High / Low of Anuh Pharma Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Anuh Pharma Ltd stocks is ₹265/150.

What is the Stock P/E of Anuh Pharma Ltd?

The Stock P/E of Anuh Pharma Ltd is 15.8.

What is the Book Value of Anuh Pharma Ltd?

The Book Value of Anuh Pharma Ltd is 60.5.

What is the Dividend Yield of Anuh Pharma Ltd?

The Dividend Yield of Anuh Pharma Ltd is 1.57 %.

What is the ROCE of Anuh Pharma Ltd?

The ROCE of Anuh Pharma Ltd is 25.6 %.

What is the ROE of Anuh Pharma Ltd?

The ROE of Anuh Pharma Ltd is 19.5 %.

What is the Face Value of Anuh Pharma Ltd?

The Face Value of Anuh Pharma Ltd is 5.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Anuh Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE